AKR1C1 has been proposed as a target for the anti-tumor compound wentilactone A in SCLC cells [121]; indeed, the aldo-keto reductases are considered as biomarkers for NRF2 status in human tumors [120]. This evidence concerns the gene NFE2L2 and neoplasm.